GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Titration] 12 weeks per step is not too slow, it is just unfashionable — 51 comments in the full submission. View in context.
1.8k
c/tirzepatide·submitted 15 days ago by u/elin_varga

[Titration] 12 weeks per step is not too slow, it is just unfashionable

Titrationbranch of 6 comments

The title is the argument: 12 weeks per step is not too slow, it is just unfashionable. Here is the rest of it. Pulling the figures out of the title: 12 weeks. All of it is written down as it happened rather than reconstructed. Research-use-only material is not approved for human use. Anything in this thread about…

Read the full submission and all 51 comments →

This branch

6 comments, started 14 days ago
u/spain_receta66 points·14 days ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/noor_hovland40 points·14 days ago

Week 88 was the first time the scale moved after a five-week stall. I changed nothing in that window.

replysharereportpermalink
u/ahmed_iyer11 points·13 days ago

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

replysharereportpermalink
u/amara_halonen15 points·13 days ago

sulphur burps are the signature complaint and they are not dangerous

replysharereportpermalink
u/ferritin_low10 points·13 days ago

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

replysharereportpermalink
u/sofia_nascimento2 points·13 days ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.